文献速递瓣膜外科

生物瓣三尖瓣置换术的长期结局:多中心研究

Long-term outcomes after bioprosthetic tricuspid valve replacement: a multicenter study.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

本研究为多中心回顾性研究,纳入7国10个高容量中心的675例生物瓣三尖瓣置换患者,其中358例(53%)为孤立手术,317例(47%)为合并手术。合并手术组感染、房室传导阻滞、多器官衰竭发生率及30天死亡率均显著高于孤立手术组。总体30天死亡率为10.4%,5年、10年、15年累积死亡率分别为27.2%、46.2%、60.6%;再干预风险在10年后显著上升,15年累积再干预率为23.3%。

要点

  • 生物瓣三尖瓣置换术后早期和长期死亡率较高,30天死亡率为10.4%。
  • 合并手术组30天死亡率14.6%,显著高于孤立手术组的6.74%(P=0.001)。
  • 再干预风险在术后10年后显著增加,15年累积再干预率为23.3%。

核心结论

  • 生物瓣三尖瓣置换是瓣膜疾病的有效治疗,但早期和长期死亡率相对较高,10年后结构瓣膜退变风险显著上升。

研究设计与样本

  • 多中心回顾性研究,纳入7个国家10个高容量中心的675例接受生物瓣三尖瓣置换的患者。

主要发现

  • 总体30天死亡率为10.4%(70例),合并手术组为14.6%(46例),孤立手术组为6.74%(24例),P=0.001。
  • 5年、10年、15年累积死亡率分别为27.2%、46.2%、60.6%。
  • 5年、10年、15年累积再干预率分别为6.1%、10.8%、23.3%,10年后再干预风险显著增加。
  • 15年免于三尖瓣再干预、起搏器植入、三尖瓣心内膜炎和主要血栓栓塞事件的比率分别为56.5%、77.3%、84.0%和86.4%。

临床怎么用

  • 生物瓣三尖瓣置换术后需关注早期死亡风险,尤其合并手术患者。
  • 长期随访应监测结构瓣膜退变,10年后再干预风险显著增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Long-term evidence about bioprosthetic tricuspid valve replacement is scarce. This study aims to investigate the long-term clinical outcomes of patients who underwent tricuspid valve replacement with bioprostheses. METHODS: This multicentre retrospective study included patients from 10 high-volume centres in 7 different countries, who underwent tricuspid valve replacement with bioprostheses. Echocardiographic and clinical data were reviewed. Long-term outcomes were investigated using Kaplan-Meier estimates, Cox regression, and competing risk analysis. RESULTS: Of 675 patients, isolated tricuspid valve replacement was performed in 358 patients (53%), while 317 (47%) underwent concomitant procedures. Between these 2 groups, patients who underwent combined procedures reported a significantly higher incidence of infection, atrioventricular block, multi-organ failure, longer intensive care unit and hospital stay and higher 30-day mortality over patients who underwent isolated procedure. The overall 30-day mortality occurred in 70 patients (10.4%) [46 (14.6%) combined vs 24 (6.74%) isolated, P = 0.001]. During the follow-up, there was a continuous rate of attrition due to death, with cumulative incidences of death at 5, 10 and 15 years being 27.2%, 46.2% and 60.6%, respectively. In contrast, the risk of reintervention starts to significantly increase after 10 years of follow-up, with cumulative incidences of reintervention being 6.1%, 10.8% and 23.3%, respectively. Freedom from tricuspid valve reintervention, pacemaker implantation, tricuspid valve endocarditis and major thromboembolic events at 15 years were 56.5%, 77.3%, 84.0% and 86.4%, respectively. CONCLUSIONS: Tricuspid valve replacement with bioprostheses is an effective treatment for valvular disease, despite being associated with relatively high early and long-term mortality. However, the risk of structural valve degeneration rises significantly after 10 years.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Piperata A, Van den Eynde J, Marin-Cuartas M, et al. Long-term outcomes after bioprosthetic tricuspid valve replacement: a multicenter study. Eur J Cardiothorac Surg. 2025. PMID: 40128150. doi:10.1093/ejcts/ezaf107

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。